"Synthetic biology tools like optogenetics allow us to precisely tune complex cellular processes, something traditional drug screening cannot do," said Maxwell Wilson, Ph.D., Co-Founder and Chief ...

A novel optogenetic screening platform enables a high-throughput screen and identified several integrated stress response-potentiating compounds.

A landmark study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by ...

GlaxoSmithKline is investing in artificial intelligence (AI) with the hope of radically cutting the time and money needed to develop a drug.

On this episode of Fortune’s Leadership Next podcast, cohosts Diane Brady, executive editorial director of the Fortune CEO ...

Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...

A major scientific advance in protein modeling developed by Microsoft Research AI for Science, has been published in Science.

Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 mil | ...

Prof. Hening Lin brings expertise in enzymes to UChicago, bridging scientists, engineers and doctors to translate research to ...

Molecular glues, tiny molecules that connect one protein to another, are promising targets for pharmaceutical research. By ...

A framework for expanding discovery efforts with compressed phenotypic screens Sample, financial and labor requirements are key barriers to scaling up high-content phenotypic discovery efforts.

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...